SNBL At a Glance
Company introduction movie
Quick guide
Q. What does SNBL do?
We focus on the life sciences field, primarily engaging in three main businesses centered around contract research and development of pharmaceuticals for pharmaceutical companies.
- CRO business that undertakes all processes of pharmaceutical development
- TR business that supports research and development using our proprietary nasal drug delivery technology, and discovers promising seeds and groundbreaking technologies from domestic and international universities and research institutions
- Medipolis business that leverages Kagoshima's natural capital for environmentally conscious projects (social benefit creation business)
The general flow (process) of pharmaceutical development is as follows.
Q. What are the strengths of SNBL ?
We are Japan's first non-clinical CRO. We seamlessly operate from non-clinical to clinical stages and have a global presence. For more details Our Business Please see.
Q. What is the TR business?
TR (Translational Research) means "bridging research" from basic research to clinical practice. AtSNBL , we are developing businesses that discover promising seeds and groundbreaking new technologies born from basic research at universities and bio-ventures in Japan and overseas, increase added value, and lead to commercialization. In addition, we are developing new drugs by applying our proprietary nasal administration technology. For details Here Please see.
Q. Can you tell us about the company's history?
SNBL was founded in 1957 in Kagoshima, Japan. We developed our business as the first CRO in Japan, listed on the Tokyo Stock Exchange in 2004, and have been listed on the Prime Market of the Tokyo Stock Exchange since 2022. The number of employees exceeds 2,000 for the entire Group, including affiliated companies.
Q. Can you provide details on your performance?
For the fiscal year ending March 2024, on a consolidated basis, we recorded sales of 26.45 billion yen, operating profit of 3.47 billion yen, ordinary profit of 6.39 billion yen, and net profit attributable to the parent company's shareholders of 3.97 billion yen. The core CRO business continued to drive growth, and sales reached a record high for the second consecutive period. Operating profit, which had been setting record highs for four consecutive periods, decreased by 1.08 billion yen (20.6%) to 4.16 billion yen compared to the previous year. The main reason for this was the recording of 1.34 billion yen in expenses for half a year from the acquisition of Satsuma Corporation last June. The increase in costs due to strategically large upfront investments was also a factor in the profit decline. The dividend is maintained at a record high of 50 yen per share.
Q. What kind of people work at your company?
About half of the employees at SNBL are women, and there are people of various nationalities working there, as well as from outside Kagoshima Prefecture. Not only in the sciences, but also in a wide range of fields, many specialists support the development of the business. For details Here Please see.
Q. Where are your locations?
In addition to Kagoshima, Wakayama, Tokyo, Osaka, and Nagano, we have bases in countries such as the United States and Cambodia. We have received numerous business requests from overseas clients and are thriving as a global company. For more details, Here Please see.
Q. What kind of company are you aiming to become?
We are actively pursuing new initiatives to become a company where everyone can work happily and enjoyably. We believe that 'human resources' are the most important strategic core for building competitive advantage and differentiating from other companies, and we consider 'developing people' as the foundation of our management. For more details Here Please see.
Q. What kind of social contribution activities do you engage in as a company?
A popular white tiger at the Hirakawa Zoological Park in Kagoshima City. In fact, it was donated bySNBL . As an official top partner of Kagoshima United FC, a local soccer club team that is active in J2, we are also contributing to regional revitalization and international goodwill through football. Medipolis International Proton Therapy Center was established by us and supports its operation. Here, we treat more than 5,300 cancer patients and contribute to improving their quality of life. Veritas Gakuen, an international school, is supported by our company and supports the multicultural education of children (0~6 years old). Overseas, we have opened a free school in Cambodia, where about 200 children are studying. In the Kingdom of Bhutan, a yogurt and cheese factory was built to improve the infant mortality rate. For details Here Please see.